Pharmaceutical

FORE Biotherapeutics raises funding to expedite plixorafenib development

FORE Biotherapeutics has raised $75m in its Series D investment round led by SR One to expedite the clinical development of plixorafenib.

Aug 24, 2023 - 20:00
FORE Biotherapeutics raises funding to expedite plixorafenib development
FORE Biotherapeutics has raised $75m in its Series D investment round led by SR One to expedite the clinical development of plixorafenib.
Read the original article

Tags:

Previous Article

XNK partners with Swedish hospital to develop AML therapy

Next Article

Japan grants patent for BioArctic’s Parkinson’s disease antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Drug middlemen switch tactics, but the outcome is the same: high prices

STAT+: Drug middlemen switch tactics, but the outcome i...

Mar 30, 2023

These proteins could predict dementia risk decades before symptoms, new study suggests

These proteins could predict dementia risk decades befo...

Jul 20, 2023

STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more

STAT+: Pharmalittle: We’re reading about Novo buying Ca...

Feb 5, 2024